Physician profile
Nikki Joy Mann
NPI 1336278753
$4,389.78
in general payments reported to CMS, 2019-2025
24 companies · $1,007 in 2025
The $1,007 reported for 2025 was more than what 85% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $517 · 2022: $1,406 · 2023: $846 · 2024: $614 · 2025: $1,007.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,367 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,367.04 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $846.40 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $707.34 | 2021-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Neurocrine Biosciences, INC. | $414.42 | 2021-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $331.86 | 2021-2025 | Caplyta |
| Lundbeck LLC | $309.31 | 2021-2025 | Rexulti, Abilify Maintena |
| Acadia Pharmaceuticals INC | $306.75 | 2022-2024 | Nuplazid |
| Alkermes, INC. | $286.58 | 2021-2025 | Aristada, Lybalvi |
| Abbvie INC. | $281.72 | 2021-2025 | |
| Ironshore Pharmaceuticals INC. | $128.89 | 2022-2023 | Jornay Pm |
| Janssen Pharmaceuticals, INC | $124.63 | 2022-2025 | Spravato, Invega Sustenna |
| Axsome Therapeutics, INC. | $112.54 | 2023-2025 | Auvelity, Sunosi |
| E.R. Squibb & Sons, L.L.C. | $95.32 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $83.04 | 2022-2025 | Trintellix |
| Corium, LLC | $75.32 | 2022-2023 | Azstarys |
| Neos Therapeutics, LP | $51.86 | 2023 | Adzenys Xr-Odt |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $47.71 | 2021 | |
| Indivior INC. | $41.10 | 2021-2023 | Perseris |
| Owp Pharmaceuticals, INC. | $32.79 | 2021-2022 | |
| Eisai INC. | $31.11 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $20.08 | 2025 | Fanapt |
| Idorsia Pharmaceuticals US INC | $19.42 | 2025 | Quviviq |
| Tris Pharma INC | $15.43 | 2023 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $15.05 | 2025 | Qelbree |
| Brainsway USA INC | $11.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nikki Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.